Pathologic correlation of 18F-16β-fluoro-5α-dihydrotestosterone (FDHT) and FDG PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Jarett L. Feldman
No relevant relationships to disclose
Josef J. Fox
No relevant relationships to disclose
Danny F. Martinez
No relevant relationships to disclose
Karen A. Autio
No relevant relationships to disclose
Jeremy C. Durack
No relevant relationships to disclose
John Humm
No relevant relationships to disclose
Heiko Schöder
No relevant relationships to disclose
Somali C. Gavane
No relevant relationships to disclose
Kristen Rebecca Curtis
No relevant relationships to disclose
Samantha Meredith Balakirsky
No relevant relationships to disclose
Rachel Mathilda Cohen
No relevant relationships to disclose
Howard I. Scher
Consultant or Advisory Role - Bristol-Myers Squibb (U); Celgene (U); Exelixis (U); Janssen Diagnostics (U); Janssen Pharmaceutical (U); Medivation (U); Millennium; Orion-Endo Pharmaceuticals
Research Funding - Janssen Diagnostics; Janssen Pharmaceutical ; Medivation
Steven M. Larson
No relevant relationships to disclose
Michael J. Morris
Consultant or Advisory Role - Bayer (U); Janssen (U); Millennium
Research Funding - Bayer; Sanofi